[Co-tetroxazin (Tibirox) and doxycycline (Vibramycin) in treatment of upper respiratory tract infections: a double-blind study].
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004318:Doxycycline / Q000627:therapeutic use*; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010033:Otitis Media / Q000188:drug therapy; D011743:Pyrimidines / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy; D013411:Sulfadiazine / Q000627:therapeutic use*; D014069:Tonsillitis / Q000188:drug therapy
D000890:Anti-Infective Agents; D004338:Drug Combinations; D011743:Pyrimidines; D013411:Sulfadiazine; C026860:sulfadiazine, tetroxoprim drug combination; D004318:Doxycycline
Co-tetroxazin (Tibirox) und Doxycyclin (Vibramycin) in der Behandlung von Infekten der Oberen Luftwege: eine Doppelblindstudie.